CMFRI signs MoU to launch product from seaweeds to combat fatty liver disease Metro Vaartha dated 20th December 2022

CMFRI, Library (2022) CMFRI signs MoU to launch product from seaweeds to combat fatty liver disease Metro Vaartha dated 20th December 2022. Metro Vaartha.

Preview

Text Metro Vaartha_20-12-2022.pdf Download (79kB) | Preview

Abstract

The Central Marine Fisheries Research Institute (CMFRI) has signed an MoU for the production of Cadalmin LivCure extract, a patent-protected nutraceutical product from seaweeds, to combat non-alcoholic fatty liver disease (NAFLD). A Memorandum of Understanding (MoU) was inked with Emineotech, a private limited company dealing with health products, for commercial production and marketing of the product.

Item Type:	Article
Subjects:	CMFRI News Clippings
Divisions:	CMFRI-Kochi > Marine Biotechnology, Fish Nutrition and Health Division Subject Area > CMFRI > CMFRI-Kochi > Marine Biotechnology, Fish Nutrition and Health Division CMFRI-Kochi > Marine Biotechnology, Fish Nutrition and Health Division Subject Area > CMFRI-Kochi > Marine Biotechnology, Fish Nutrition and Health Division
Depositing User:	Mr. Augustine Sipson N A
Date Deposited:	28 Dec 2022 07:08
Last Modified:	28 Dec 2022 07:08
URI:	http://eprints.cmfri.org.in/id/eprint/16560

Actions (login required)

View Item